Jochen Gerhard Hofstaetter
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jochen Gerhard Hofstaetter has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Jennyfer Angel Mitterer
Michael Ogon Laboratory for Orthopedic Research, Orthopedic Hospital Vienna Speising, Vienna, Austria
9 shared publications Bernhard J.H. Frank
Michael Ogon Laboratory for Orthopaedic Research, Orthopaedic Hospital Speising, Vienna, Austria; AUVA Trauma Center Vienna, Lorenz Boehler, Austria
5 shared publicationsMartin Dominkus
2nd Department, Orthopaedic Hospital Speising, Vienna, Austria
5 shared publicationsSebastian Simon
Michael Ogon Laboratory for Orthopedic Research, Orthopedic Hospital Vienna Speising, Vienna, Austria; Department for Trauma Surgery, AUVA Trauma Center Meidling, Vienna, Austria
5 shared publications- Sujeesh Sebastian
Michael Ogon Laboratory for Orthopaedic Research, Orthopaedic Hospital Speising, Vienna, Austria
5 shared publications Alexander Aichmair
Michael Ogon Laboratory for Orthopaedic Research, Orthopaedic Hospital Speising, Vienna, Austria; 2nd Department, Orthopaedic Hospital Speising, Vienna, Austria
4 shared publications
Latest Publications
- 8 May 2026
- Published by Elsevier in The Journal of Arthroplasty
- Vol. 41 (6) , e64-e66
Reply to Letter Regarding “Comparison of Cutibacterium Avidum Versus Acnes in Periprosthetic Hip Infections: A Matched Cohort Analysis”
- 8 May 2026
- Published by Elsevier in The Journal of Arthroplasty
- Vol. 41 (6) , e64-e66
Reply to Letter Regarding “Comparison of Cutibacterium Avidum Versus Acnes in Periprosthetic Hip Infections: A Matched Cohort Analysis”
- Open Access
- 24 February 2026
- Published by Elsevier in The Journal of Arthroplasty
- Vol. 41 (11) , 3480-3489
Beyond Gram-Negative and Gram-Positive Bacteria: Virulence as a Determinant of Clinical Outcome in Periprosthetic Joint Infections
- 24 February 2026
- Published by Elsevier in The Journal of Arthroplasty
- Vol. 41 (11) , 3480-3489
Open AccessBeyond Gram-Negative and Gram-Positive Bacteria: Virulence as a Determinant of Clinical Outcome in Periprosthetic Joint Infections
- Open Access
- 19 January 2026
- Published by Wiley in Knee Surgery, Sports Traumatology, Arthroscopy
- Vol. 34 (10) , 3627-3636
Synovial interleukin‐6 point‐of‐care testing, alone and combined with D‐dimer, supports rapid diagnosis of periprosthetic joint infection
Purpose: Data on the reliability of point‐of‐care (POC) tests for the rapid diagnosis of periprosthetic joint infections (PJI) using synovial fluid (SF) D‐dimer (DD), interleukin 6 (IL‐6) and procalcitonin (PCT) are limited. This study aimed to address this issue by evaluating the diagnostic accuracy of POC tests for SF DD, IL‐6 and PCT in comparison to standard laboratory devices for diagnosing PJI. Methods: A total of 273 patients who underwent 300 revision arthroplasties were included in this study. According to the European Bone and Joint Infection criteria, 123 were classified as infected, 145 as aseptic revisions and 32 as likely infected. SF DD, IL‐6 and PCT levels were quantified using both POC and standard laboratory tests. The diagnostic accuracy was assessed using receiver operating characteristic curves and area under the curve (AUC). Results: Among POC tests, IL‐6 demonstrated the highest AUC 0.83 (95% confidence interval CI 0.77–0.89), followed by DD (0.66, 95% CI 0.59–0.72), while PCT performed poorly (AUC 0.26, 95% CI 0.20–0.33). Laboratory‐based IL‐6 test outperformed all other markers (AUC 0.94, 95% CI 0.90–0.97). When using both POC and standard laboratory methods, significant differences were noted for IL‐6 and DD ( p < 0.001). Combining the POC test results for IL‐6 and DD showed better diagnostic performance than either alone (AUC 0.92). In patients with PJI, biomarker levels differed by pathogen virulence, except for POC IL‐6 ( p = 0.631), POC DD ( p = 0.080) and laboratory DD ( p = 0.053). Conclusions: POC tests for SF, particularly those for IL‐6, support the rapid PJI diagnosis, and combining POC IL‑6 with DD further improves diagnostic accuracy. These findings suggest that POC IL‐6, either independently or in conjunction with DD, could be useful in situations where rapid decisions are required. However, its inferior performance compared to that of laboratory assays highlights the need for further optimisation and validation. Level of Evidence: Level II, development of diagnostic criteria in a consecutive series of patients and a universally applied ‘gold’ standard.
- 19 January 2026
- Published by Wiley in Knee Surgery, Sports Traumatology, Arthroscopy
- Vol. 34 (10) , 3627-3636
Open AccessSynovial interleukin‐6 point‐of‐care testing, alone and combined with D‐dimer, supports rapid diagnosis of periprosthetic joint infection
Purpose: Data on the reliability of point‐of‐care (POC) tests for the rapid diagnosis of periprosthetic joint infections (PJI) using synovial fluid (SF) D‐dimer (DD), interleukin 6 (IL‐6) and procalcitonin (PCT) are limited. This study aimed to address this issue by evaluating the diagnostic accuracy of POC tests for SF DD, IL‐6 and PCT in comparison to standard laboratory devices for diagnosing PJI. Methods: A total of 273 patients who underwent 300 revision arthroplasties were included in this study. According to the European Bone and Joint Infection criteria, 123 were classified as infected, 145 as aseptic revisions and 32 as likely infected. SF DD, IL‐6 and PCT levels were quantified using both POC and standard laboratory tests. The diagnostic accuracy was assessed using receiver operating characteristic curves and area under the curve (AUC). Results: Among POC tests, IL‐6 demonstrated the highest AUC 0.83 (95% confidence interval CI 0.77–0.89), followed by DD (0.66, 95% CI 0.59–0.72), while PCT performed poorly (AUC 0.26, 95% CI 0.20–0.33). Laboratory‐based IL‐6 test outperformed all other markers (AUC 0.94, 95% CI 0.90–0.97). When using both POC and standard laboratory methods, significant differences were noted for IL‐6 and DD ( p < 0.001). Combining the POC test results for IL‐6 and DD showed better diagnostic performance than either alone (AUC 0.92). In patients with PJI, biomarker levels differed by pathogen virulence, except for POC IL‐6 ( p = 0.631), POC DD ( p = 0.080) and laboratory DD ( p = 0.053). Conclusions: POC tests for SF, particularly those for IL‐6, support the rapid PJI diagnosis, and combining POC IL‑6 with DD further improves diagnostic accuracy. These findings suggest that POC IL‐6, either independently or in conjunction with DD, could be useful in situations where rapid decisions are required. However, its inferior performance compared to that of laboratory assays highlights the need for further optimisation and validation. Level of Evidence: Level II, development of diagnostic criteria in a consecutive series of patients and a universally applied ‘gold’ standard.
- Open Access
- 19 November 2025
- Published by Wolters Kluwer Health in Journal of Bone and Joint Surgery
- Vol. 107 (22) , 2561-2573
Synovial Fluid MicroRNA Biomarkers Enable Accurate Diagnosis of Hip and Knee Periprosthetic Joint Infections
Background: Diagnosing hip and knee periprosthetic joint infections (PJIs) is challenging, necessitating sensitive and specific biomarkers for accurate diagnosis. Cell-free microRNAs (miRNAs) are emerging as noninvasive biomarkers. We hypothesized that hip and knee PJIs are associated with unique cell-free miRNA profiles in synovial fluid, which can be used for the diagnosis of infection. Methods: Synovial fluid samples from 173 Caucasian patients undergoing septic or aseptic revision total joint replacement (TJR) of the hip or knee, as well as samples from 6 osteoarthritic knees, were analyzed. The samples were divided into a discovery group (40 samples; 50% septic) and a validation cohort (133 samples; 35% septic). Small RNA next-generation sequencing (NGS) was used to screen miRNAs in the discovery samples, with reverse transcription-quantitative polymerase chain reaction (RT-qPCR) used to confirm the NGS findings and to validate results in the independent, larger cohort. Logistic regression and cross-validation were applied to assess the diagnostic power of individual and combined miRNAs. Results: NGS identified 132 miRNAs with significant differences (false discovery rate < 0.05) between the septic and aseptic synovial fluid samples. Of these, 18 miRNAs were further analyzed with use of RT-qPCR in the independent cohort, with miR-223-3p and miR-338-5p showing the highest increases in septic synovial fluid (log 2 fold change >4) and miR-151a-3p and miR-214-3p showing the most substantial reductions. To investigate the performance of the multivariable models, logistic regression was performed by dividing the cohort into a training set (60%) and a test set (40%), which showed improved performance relative to that of the univariate models (median area under the curve [AUC] for the multivariable models, 0.96). A subgroup analysis by joint type, gender, and synovial fluid sample preparation confirmed robust miRNA biomarker performance for PJI. Conclusions: Cell-free miRNA levels in the synovial fluid of patients undergoing septic hip or knee TJR were altered in response to infection, indicating immune cell activity in the joint. These miRNAs offer sensitive and specific pathogen-independent biomarkers with potential clinical applications in the diagnosis of hip and knee PJI. Level of Evidence: Diagnostic Level III . See Instructions for Authors for a complete description of levels of evidence.
- 19 November 2025
- Published by Wolters Kluwer Health in Journal of Bone and Joint Surgery
- Vol. 107 (22) , 2561-2573
Open AccessSynovial Fluid MicroRNA Biomarkers Enable Accurate Diagnosis of Hip and Knee Periprosthetic Joint Infections
Background: Diagnosing hip and knee periprosthetic joint infections (PJIs) is challenging, necessitating sensitive and specific biomarkers for accurate diagnosis. Cell-free microRNAs (miRNAs) are emerging as noninvasive biomarkers. We hypothesized that hip and knee PJIs are associated with unique cell-free miRNA profiles in synovial fluid, which can be used for the diagnosis of infection. Methods: Synovial fluid samples from 173 Caucasian patients undergoing septic or aseptic revision total joint replacement (TJR) of the hip or knee, as well as samples from 6 osteoarthritic knees, were analyzed. The samples were divided into a discovery group (40 samples; 50% septic) and a validation cohort (133 samples; 35% septic). Small RNA next-generation sequencing (NGS) was used to screen miRNAs in the discovery samples, with reverse transcription-quantitative polymerase chain reaction (RT-qPCR) used to confirm the NGS findings and to validate results in the independent, larger cohort. Logistic regression and cross-validation were applied to assess the diagnostic power of individual and combined miRNAs. Results: NGS identified 132 miRNAs with significant differences (false discovery rate < 0.05) between the septic and aseptic synovial fluid samples. Of these, 18 miRNAs were further analyzed with use of RT-qPCR in the independent cohort, with miR-223-3p and miR-338-5p showing the highest increases in septic synovial fluid (log 2 fold change >4) and miR-151a-3p and miR-214-3p showing the most substantial reductions. To investigate the performance of the multivariable models, logistic regression was performed by dividing the cohort into a training set (60%) and a test set (40%), which showed improved performance relative to that of the univariate models (median area under the curve [AUC] for the multivariable models, 0.96). A subgroup analysis by joint type, gender, and synovial fluid sample preparation confirmed robust miRNA biomarker performance for PJI. Conclusions: Cell-free miRNA levels in the synovial fluid of patients undergoing septic hip or knee TJR were altered in response to infection, indicating immune cell activity in the joint. These miRNAs offer sensitive and specific pathogen-independent biomarkers with potential clinical applications in the diagnosis of hip and knee PJI. Level of Evidence: Diagnostic Level III . See Instructions for Authors for a complete description of levels of evidence.
- 9 October 2025
- Published by Elsevier in The Journal of Arthroplasty
- Vol. 41 (6) , 1857-1865
Comparison of Cutibacterium avidum Versus acnes in Periprosthetic Hip Infections: A Matched Cohort Analysis
- 9 October 2025
- Published by Elsevier in The Journal of Arthroplasty
- Vol. 41 (6) , 1857-1865
Comparison of Cutibacterium avidum Versus acnes in Periprosthetic Hip Infections: A Matched Cohort Analysis
- Open Access
- 1 October 2025
- Published by Wolters Kluwer Health in JBJS Open Access
- Vol. 10 (4)
Dual Antibiotic Prophylaxis with Addition of Doxycycline Does Not Lower Periprosthetic Infection Rate in Primary Directed Anterior Total Hip Replacement
Background: Periprosthetic joint infections (PJI) caused by Cutibacterium spp. are frequently observed in total hip arthroplasty (THA) using the direct anterior approach (DAA). The microbiological spectrum of PJI after DAA differs from that of a lateral based approach. The aim of this study was to compare a dual-antibiotic (AB)-prophylaxis with cefuroxime (CEF) and doxycycline (DOX) to mono-AB-prophylaxis with CEF alone in DAA THA. Methods: A total of 4,430 primary THAs receiving CEF prophylaxis were compared with 3,487 THAs receiving CEF+DOX prophylaxis. The institutional AB-prophylaxis was changed from cefuroxime 1.5-3 g (CEF group) alone to cefuroxime 1.5-3 doxycycline 300 mg (CEF+DOX group). A multivariable binary logistic regression analysis to evaluate the association between CEF vs. CEF+DOX and the occurrence of PJI (according to the International Consensus Meeting 2018) was performed with dropping 3 months before and after the change (covariates: American Society of Anesthesiologists, Charlson Comorbidity -Index, age, body mass index [BMI], smoking status, and diabetes mellitus [DM]). The primary outcome was the incidence of PJI following THA after a minimum follow-up of 1 year, with an accompanying analysis of the microbiological spectrum. Results: In total, 7,917 (age: 65.8 (65.5; 66.0) years; female: 61.2%; male: 38.8%) THA were analyzed for this study. After a median follow-up of 4.3 years (interquartile-range: 2.0-6.2), no significant difference in the incidence of septic revision was observed between the CEF and CEF+DOX therapy with an infection rate of 1.3% and 1.0%, respectively (p = 0.172). The septic-free revision rate at 1 year was 99.0% in the CEF group and 99.1% in the CEF+DOX group (p = 0.541). Due to the longer follow-up, the CEF group experienced more THA with aseptic loosening compared to the CEF+DOX group. The type of AB prophylaxis was not associated with a clinically relevant higher risk of PJI (odds ratio [OR] = 1.03; 95% CI: 0.99-1.07; p = 0.052). Only BMI demonstrated a significant association with PJI (OR = 1.12; 95% CI: 1.09-1.16; p < 0.001). In the CEF+DOX group, Cutibacterium avidum was more frequent (15.7% vs. 8.1%) and Cutibacterium Acnes was less frequent (9.8% vs. 12.3%) compared with the CEF group (p = 0.143 and p = 0.809, respectively). Conclusion: This study showed no superiority in the rate of PJI between CEF+DOX and CEF alone in DAA THA. DOX does not prevent Cutibacterium -positive PJIs. There are factors other than AB prophylaxis that influence the risk of PJI. Level of Evidence: Diagnostic Level III . See Instructions for Authors for a complete description of levels of evidence.
- 1 October 2025
- Published by Wolters Kluwer Health in JBJS Open Access
- Vol. 10 (4)
Open AccessDual Antibiotic Prophylaxis with Addition of Doxycycline Does Not Lower Periprosthetic Infection Rate in Primary Directed Anterior Total Hip Replacement
Background: Periprosthetic joint infections (PJI) caused by Cutibacterium spp. are frequently observed in total hip arthroplasty (THA) using the direct anterior approach (DAA). The microbiological spectrum of PJI after DAA differs from that of a lateral based approach. The aim of this study was to compare a dual-antibiotic (AB)-prophylaxis with cefuroxime (CEF) and doxycycline (DOX) to mono-AB-prophylaxis with CEF alone in DAA THA. Methods: A total of 4,430 primary THAs receiving CEF prophylaxis were compared with 3,487 THAs receiving CEF+DOX prophylaxis. The institutional AB-prophylaxis was changed from cefuroxime 1.5-3 g (CEF group) alone to cefuroxime 1.5-3 doxycycline 300 mg (CEF+DOX group). A multivariable binary logistic regression analysis to evaluate the association between CEF vs. CEF+DOX and the occurrence of PJI (according to the International Consensus Meeting 2018) was performed with dropping 3 months before and after the change (covariates: American Society of Anesthesiologists, Charlson Comorbidity -Index, age, body mass index [BMI], smoking status, and diabetes mellitus [DM]). The primary outcome was the incidence of PJI following THA after a minimum follow-up of 1 year, with an accompanying analysis of the microbiological spectrum. Results: In total, 7,917 (age: 65.8 (65.5; 66.0) years; female: 61.2%; male: 38.8%) THA were analyzed for this study. After a median follow-up of 4.3 years (interquartile-range: 2.0-6.2), no significant difference in the incidence of septic revision was observed between the CEF and CEF+DOX therapy with an infection rate of 1.3% and 1.0%, respectively (p = 0.172). The septic-free revision rate at 1 year was 99.0% in the CEF group and 99.1% in the CEF+DOX group (p = 0.541). Due to the longer follow-up, the CEF group experienced more THA with aseptic loosening compared to the CEF+DOX group. The type of AB prophylaxis was not associated with a clinically relevant higher risk of PJI (odds ratio [OR] = 1.03; 95% CI: 0.99-1.07; p = 0.052). Only BMI demonstrated a significant association with PJI (OR = 1.12; 95% CI: 1.09-1.16; p < 0.001). In the CEF+DOX group, Cutibacterium avidum was more frequent (15.7% vs. 8.1%) and Cutibacterium Acnes was less frequent (9.8% vs. 12.3%) compared with the CEF group (p = 0.143 and p = 0.809, respectively). Conclusion: This study showed no superiority in the rate of PJI between CEF+DOX and CEF alone in DAA THA. DOX does not prevent Cutibacterium -positive PJIs. There are factors other than AB prophylaxis that influence the risk of PJI. Level of Evidence: Diagnostic Level III . See Instructions for Authors for a complete description of levels of evidence.
- 26 May 2025
- Published by Elsevier in The Journal of Arthroplasty
- Vol. 40 (12) , 3315-3323
Rate- and Patient-Specific Risk Factors for Periprosthetic Acetabular Fractures During Primary Total Hip Arthroplasty Using a Press-Fit Cup
- 26 May 2025
- Published by Elsevier in The Journal of Arthroplasty
- Vol. 40 (12) , 3315-3323
Rate- and Patient-Specific Risk Factors for Periprosthetic Acetabular Fractures During Primary Total Hip Arthroplasty Using a Press-Fit Cup